MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2018 International Congress

    Decreased blood beta-Glucosidase activity and GBA mutations in Dystonia

    S. Schreglmann, D. Burke, A. Batla, N. Kresojevic, N. Wood, S. Heales, K. Bhatia (London, United Kingdom)

    Objective: To report on the observation of decreased levels of GCase in peripheral blood in patients presenting with dystonia without signs of parkinsonism. Background: Glucocerebrosidase…
  • 2018 International Congress

    Striatum of the ouabain-induced pharmacological DYT12 mouse model is affected by structural and metabolic abnormalities

    L. Rauschenberger, Y. Al-Zuraiqi, J. Volkmann, C.W. Ip (Wuerzburg, Germany)

    Objective: To study changes in neuronal morphology and neurotransmitter metabolism in the striatum of a pharmacological DYT12 mouse model after induction of a dystonic phenotype…
  • 2018 International Congress

    Parkinson’s Disease Risk in Breast Cancer

    R. Mills-Joseph (Columbus, OH, USA)

    Objective: Case report of two patients who developed symptoms of Parkinson’s disease after treatment with chemotherapy and radiation for breast cancer and to review the…
  • 2018 International Congress

    Droxidopa and Midodrine Treatment Persistence in Patients with Orthostatic Hypotension

    S. Kymes, K. Jackson, M. Widolff, C. Sullivan, L. Hewitt, S. Raj (Deerfield, IL, USA)

    Objective: To determine the treatment persistence of droxidopa and midodrine in patients with orthostatic hypotension (OH) or neurogenic orthostatic hypotension (nOH) when medication cost was…
  • 2018 International Congress

    Treating Huntington’s Disease using a holistic approach

    T. Sinha (Patna, India)

    Objective: Huntington’s disease (HD) is a fatal genetic disorder that causes the progressive breakdown of nerve cells in the brain. It deteriorates a person’s physical…
  • 2018 International Congress

    On the hunt for a link between genetically confirmed Huntington’s disease and Amyotrophic Lateral Sclerosis

    L. Williams, K. O'Connell, D. Burke, J. Cryan, D. McCabe (Dublin, Ireland)

    Objective: To characterise the clinical and pathologic findings of Huntington’s disease (HD) and coincident amyotrophic lateral sclerosis (ALS). Background: A 66 year old man presented…
  • 2018 International Congress

    Evaluation of a driving questionnaire to facilitate awareness of issues that could compromise driving ability in a person with Parkinson’s disease

    J. Price, H. Martin, L. Ebenezer (Powys, United Kingdom)

    Objective: To evaluate the usefulness of a driving questionnaire data collection tool to assist in the ongoing monitoring and identification of issues that could compromise…
  • 2018 International Congress

    Dopaminergic stem cells reside in the rostral migratory stream

    K. Schweyer, C. Steiner, G. Höglinger, T. Rösler (Munich, Germany)

    Objective: To analyze if the adult rostral migratory stream (RMS) harbors neural stem cells with the potential to create dopaminergic neurons for the olfactory bulb…
  • 2018 International Congress

    Recruitment of Minority populations with Parkinson’s disease at an Urban Hospital

    C. Branson, S. Bissonette, T. Johnson, J. Weinberg, M. Saint-Hilaire (Boston, MA, USA)

    Objective: To evaluate diagnostic disparities in Parkinson’s disease (PD) through recruitment of underrepresented minorities into a PD screening study. Background: African-Americans are less likely than…
  • 2018 International Congress

    Cerebral and pulmonary thromboembolism in a patient with hyperhomocystinemia treated with high dose levodopa/carbidopa intestinal gel

    E. Saka Topcuoglu, L. Mehdikhanova, E. Arsava, M. Topcuoglu, B. Elibol (Ankara, Turkey)

    Objective: We report a case that developed cerebral and pulmonary thromboembolism during 24-hour levodopa/carbidopa intestinal gel (LCIG) infusion. Background: LCIG is a therapeutic option in…
  • « Previous Page
  • 1
  • …
  • 169
  • 170
  • 171
  • 172
  • 173
  • …
  • 177
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley